KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Total Liabilities (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Total Liabilities data on record, last reported at $4.0 billion in Q4 2025.

  • For Q4 2025, Total Liabilities fell 1.23% year-over-year to $4.0 billion; the TTM value through Dec 2025 reached $4.0 billion, down 1.23%, while the annual FY2025 figure was $4.0 billion, 1.23% down from the prior year.
  • Total Liabilities reached $4.0 billion in Q4 2025 per CRL's latest filing, down from $4.1 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $4.7 billion in Q3 2022 and bottomed at -$3.6 billion in Q1 2024.
  • Average Total Liabilities over 5 years is $2.5 billion, with a median of $4.2 billion recorded in 2024.
  • Peak YoY movement for Total Liabilities: soared 294.14% in 2022, then plummeted 179.51% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $4.4 billion in 2021, then grew by 3.32% to $4.6 billion in 2022, then fell by 0.94% to $4.5 billion in 2023, then dropped by 11.37% to $4.0 billion in 2024, then decreased by 1.23% to $4.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $4.0 billion in Q4 2025, $4.1 billion in Q3 2025, and $4.2 billion in Q2 2025.